Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | FOS | P01100 | 3/20 | 0.33 |
| ▸ | JUN | P05412 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.33 |
| ▸ | RELA | Q04206 | 3/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16635194 | 0.80 | TRPA1 (0.42) | TRPA1HDAC1HDAC6MAPT | |
| SCHEMBL16648043 | 0.77 | TRPA1 (0.40) | TRPA1HDAC1HDAC6HPGD | |
| SCHEMBL16635089 | 0.76 | HSP90AA1 (0.37) | TRPA1KMT2AMEN1MAPTHPGD | |
| SCHEMBL6549108 | 0.72 | KMT2A (0.40) | KDM4ENOTUMKMT2ACYP1A2CYP2C19 | |
| SCHEMBL4065146 | 0.72 | ALDH1A1 (0.39) | KDM4EKMT2ACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL17932863 | 0.71 | ALDH1A1 (0.40) | KDM4EKMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL3557936 | 0.70 | RAB9A (0.42) | KDM4ENOTUMKMT2AMEN1ALDH1A1 | |
| SCHEMBL28074578 | 0.70 | KCNT1 (0.35) | TRPA1PDE4BKMT2AMEN1CYP1A2 | |
| SCHEMBL2398779 | 0.69 | MRGPRX4 (0.40) | KDM4ENOTUMKMT2AMEN1CYP1A2 | |
| SCHEMBL17959543 | 0.69 | NOS3 (0.41) | TRPA1KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3055302-B1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3055302-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885HDAC1 1106/4885HDAC6 434/4885 |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885HDAC1 1106/4885HDAC6 434/4885 |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885HDAC1 1106/4885HDAC6 434/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885HDAC1 1106/4885HDAC6 434/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885HDAC1 1106/4885HDAC6 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.